000			04062nam a2200409 a 4500
003			EG-GiCUC
005			20260516142557.0
008			220228s2021 ua dh frm 000 0 eng d
040			_aEG-GiCUC _cEG-GiCUC _beng
041	0		_aeng _beng _bara
049			_aDeposite
082	0	4	_a540
092			_a540 _221
097			_aM.Sc
099			_aCai01.12.25.M.Sc.2022.Ma.I
100	0		_aManar Hesham Fouad, _epreparation.
245	1	0	_aImpact of notch1 signaling pathway on clinical course of pediatric t-cell acute lymphoblastic leukemia / _cby Manar Hesham Fouad ; Supervised Prof.Dr.Mahfouz Ali Abdelaziz , Prof.Dr.Nashwa Nagy Elkhazragy.
246	1	5	_aتأثير مسار نوتش على خط السير الاكلينكي لمرض سرطان الدم اللميفاوي الحاد من نوع الخلية التائية فى الأطفال
264		0	_c2022
300			_a216 Pages : _bcharts , facsimiles ; _c30 cm+ _eCD
336			_atext _2rda content
337			_aUnmediated _2rdamedia
338			_avolume _2rdacarrier
502			_aThesis (M.Sc.) - Cairo University - Faculty of Science - Department of Organic Chemistry
504			_aBibliography: pages 140-227.
520		3	_aAcute Lymphoblastic Leukemia (ALL) represents the most commonly diagnosed cancer in children. T-cell Acute Lymphoblastic Leukemia (T-cell ALL) accounts for around 10-15% of pediatric ALL cases and 25% of adult cases. Constitutive activation of Notch signaling pathway takes place, as a result of NOTCH1 activating mutations, in over 60 % of T-ALL cases. Despite the remarkable improvement that the world has witnessed over the last half-century in the prognosis of ALL, relapse is still a major challenge. Also, the increasing percentage of patients suffering from treatment-related toxicities or chemotherapeutic resistance and recurrence has indicated the inaccuracy of the currently used risk allocation schemes, which consequently explains the necessity of a more reliable assessment approach of the leukemic status. Consequently, a deeper understanding of T-ALL biology at the molecular level is urgently needed to facilitate the identification of novel diagnostic and prognostic biomarkers and therapeutic targets that can ultimately enable early detection, targeted therapy with minimal side effects, and hence a better prognosis. More attention has been paid towards investigating the direct and indirect regulatory roles that NOTCH1 plays in order to promote leukemogenesis. The oncogenic microRNA miR-21 has been implicated in several hematological malignancies and solid tumors. Its oncogenic role in T-ALL is being exhibited through targeting the tumorsuppressive programmed cell death protein 4 (PCDP4). Its aberrant expression has also been associated with a poor prognosis. On the other hand, miR-193b-3p, or miR-193b, is a wellcharacterized tumor-suppressive microRNA that is usually downregulated in a wide range of cancers. In T{u2010} cell acute lymphoblastic leukemia, miR{u2010} 193b{u2010} 3p was also found to be repressed, and its repression was negatively associated with the proto{u2010} oncogene MYB expression. Its downregulation was also found to be associated with unfavorable prognostic features. Although the Notch-regulated long non-coding RNA, LUNAR1, has been demonstrated to be among the most prominently dysregulated lncRNAs in T-ALL cases, the association of its expression levels in the peripheral blood of patients with the clinicopathological features and/or prognosis has not been assessed yet
530			_aIssued also as CD
546			_aText in English and abstract in Arabic & English.
650		0	_aBioechnology
653		1	_aALL _aMiR-21 _aNOTCH1
700	0		_aMahfouz Ali Abdelaziz _ethesis advisor.
700	0		_aNashwa Nagy Elkhazragy _ethesis advisor.
900			_b01-01-2022 _cMahfouz Ali Abdelaziz _cNashwa Nagy Elkhazragy _UCairo University _FFaculty of Science _DDepartment of Biotechnology
905			_aShimaa _eCataloger
942			_2ddc _cTH
999			_c84372